Table 3.
Adjusted impact of patient and tumor characteristics on receipt of pelvic lymph node dissection (PLND), all patients
| Characteristic | Adjusted odds ratio (95% CI) | p |
|---|---|---|
| Surgical procedure | <0.0001 | |
| MIRP | Reference | |
| ORP | 5.28 (4.56–6.81) | |
| RP, NOS | 1.26 (1.05–1.52) | |
| Age at diagnosis | NS | |
| 66–69 | Reference | |
| 70–74 | 0.95 (0.84–1.07) | |
| 75–79 | 1.33 (1.03–1.72) | |
| 80+ | 1.00 (0.48–2.12) | |
| Race | NS | |
| White | Reference | |
| Black | 0.96 (0.77–1.22) | |
| Other | 0.91 (0.75–1.11) | |
| Median income | NS | |
| 1st quartile | Reference | |
| 2nd quartile | 0.96 (0.81–1.43) | |
| 3rd quartile | 1.07 (0.89–1.28) | |
| 4th quartile | 1.08 (0.90–1.30) | |
| Urban residence | NS | |
| Metro | Reference | |
| Non-Metro | 0.94 (0.78–1.14) | |
| Geographic region | NS | |
| Northeast | Reference | |
| South | 0.88 (0.69–1.13) | |
| Midwest | 1.16 (0.90–1.46) | |
| West | 1.39 (1.15–1.68) | |
| Married | <0.0001 | |
| Yes | Reference | |
| No | 0.84 (0.70–1.10) | |
| Unknown | 0.26 (0.20–0.34) | |
| Clinical stage | NS | |
| T1 | Reference | |
| T2 | 1.08 (0.96–1.22) | |
| T3 | 1.35 (0.83–2.19) | |
| PSA | <0.001 | |
| Normal | Reference | |
| Borderline | 0.74 (0.55–1.22) | |
| Elevated | 1.35 (0.83–2.19) | |
| Numeric PSA* | <0.0001 | |
| ≤10 ng/ml | Reference | |
| >10 ng/ml | 1.77 (1.46–2.15) | |
| Gleason Score | <0.0001 | |
| 2–6 | Reference | |
| 7+ | 2.41 (1.88–3.10) | |
| Comorbidity score | NS | |
| 0 | Reference | |
| 1 | 0.89 (0.63–1.25) | |
| 2+ | 0.54 (0.27–1.09) | |
| Year of surgery | 0.67 (0.58–0.73) | <0.0001 |
MIRP: minimally invasive radical prostatectomy, ORP: open radical prostatectomy, RP, NOS: radical prostatectomy, not otherwise specified, NS: Not statistically significant at p<0.05
*
Odds ratio for numeric PSA from separate multivariable analysis limited to men diagnosed with prostate cancer in 2004–2006, adjusted for all other characteristics in table except for qualitative PSA.